BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Make your choice for a definitive Christmas getaway destination! - 2Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- 3From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- 4IDF, police arrest eleven for criminal, terror-related activity over weekend
- 5Instructions to Perform Fundamental Upkeep on Your Slam 1500.
- Vote In favor of Your Favored Kind Of Organic product
- Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- Remote Work Survival manual: Helping Efficiency at Home
- Which European palace do you fantasy about visiting? Vote!
- 6 Methods for further developing Rest Quality
- The Best Games On the planet
- 6 Famous kind of practice on the planet
- When Would it be a good idea for you to Look for Help from a Criminal Legal counselor?
